The FOXO1 specific small molecular compound AS1842856 has been analyzed as therapeutic drug for the treatment of type 2 diabetes in mice, and has been tested in regard of pulmonary hypertension and bone development. Here, FOXO1 is linked to pulmonary arterial hypertension.